Atrial Fibrillation and Cancer: a Nationwide French Cohort Study

September 29, 2022 updated by: Joachim ALEXANDRE, University Hospital, Caen

Atrial fibrillation (AF) is a common complication associated with cancer but the risk of AF according to the cancer localization and status as well as the risk of thromboembolisms, bleedings and mortality are poorly known.

The objective of this study is to use a very large French nationwide cohort to adress thèses questions.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

5000000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Tours, France, 37000
        • Service de Cardiologie, Centre Hospitalier Universitaire Trousseau

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients hospitalized from january 2010 to december 2019 and having an available ICD-10 code discharge.

Description

Inclusion Criteria:

  • adult hospitalized patients
  • with an ICD-10 code discharge from january 2010 to december 2019 in the French national hospital discharge database (PMSI Programme de Médicalisation des Systèmes d'Information)

Exclusion Criteria:

  • children

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
atrial fibrillation
Time Frame: from inclusion in the cohort up to 10 years
occurrence of atrial fibrillation
from inclusion in the cohort up to 10 years
cancer
Time Frame: ffrom inclusion in the cohort up to 10 years
occurrence of cancer
ffrom inclusion in the cohort up to 10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
thromboembolism
Time Frame: from inclusion in the cohort up to 10 years
occurrence of thromboembolism
from inclusion in the cohort up to 10 years
bleeding
Time Frame: from inclusion in the cohort up to 10 years
occurrence of bleeding
from inclusion in the cohort up to 10 years
mortality
Time Frame: from inclusion in the cohort up to 10 years
occurrence of mortality
from inclusion in the cohort up to 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Caen

Collaborators

University Hospital, Tours

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 22, 2022

Primary Completion (Anticipated)

January 1, 2030

Study Completion (Anticipated)

January 1, 2030

Study Registration Dates

First Submitted

September 24, 2022

First Submitted That Met QC Criteria

September 29, 2022

First Posted (Actual)

October 3, 2022

Study Record Updates

Last Update Posted (Actual)

October 3, 2022

Last Update Submitted That Met QC Criteria

September 29, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PMSI_092022

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on event occurence

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe